The Generative Brain

Eli Lilly and Company (owner of ST-506 and the Sangamo zinc finger and capsid platforms)

Eli Lilly is a large US pharmaceutical company that, through a 2026 bankruptcy auction, bought the prion disease gene therapy program ST-506 together with Sangamo's zinc finger, capsid delivery and MINT platforms for USD 50 million in cash. ST-506 is a one-time intravenous zinc finger repressor designed to lower the prion protein in the brain. Sangamo said in July 2026 that the new owner is expected to continue the program toward clinical studies, with possible delays. Nothing opened here shows Lilly's own plans, so timing, trial sites and access are unknown. Information only; this is not a treatment option today.

Key facts

  • Deal: Sangamo signed an asset sale agreement with Lilly on 23 June 2026 covering its capsid delivery, zinc finger and MINT platforms and ST-506, as a stalking horse bid, while opening voluntary Chapter 11 proceedings in Delaware (case 26-10989).
  • Price: after the auction Sangamo selected Lilly as successful bidder on 12 August 2026 at USD 50 million in cash at closing, within about USD 163.55 million in total winning bids.
  • Closing: Sangamo's 13 October 2026 release reports the Lilly and PTC sales have closed with USD 163.55 million received; the August release expected the Lilly closing on or about 4 September 2026 and no source opened gives the actual closing date.
  • Scope: Lilly did not buy the chronic neuropathic pain program ST-503, which went to a separate auction expected to finish in the fourth quarter of 2026; the Fabry program went to PTC Therapeutics.
  • What was bought: ST-506 is a one-time intravenous zinc finger repressor aimed at PRNP, packaged in the neuron-targeting STAC-BBB capsid.
  • State at handover: a 3-month GLP toxicology study in monkeys showed no ST-506-related adverse findings in the analyses completed; the slides say the nonclinical data support a clinical trial application, with final toxicology analyses and manufacturing still to be finished before submission.
  • Animal data: in a prion mouse model dosed after symptoms began, high-dose animals had median survival above 494 days post inoculation against 169.5 days for vehicle.
  • What Sangamo told families on 12 July 2026: the new owner is expected to continue development toward clinical studies and make the investigational treatment for a future trial, its staff would support the handover, and the program is expected to continue although there may be delays.
  • Lilly's own words: the About and Leadership pages opened carry no mention of prion disease, Sangamo or ST-506, and no Lilly statement of plans for the program was found.
  • Relevant leaders: David A. Ricks is Chair and CEO; Carole Ho leads Lilly Neuroscience; Daniel Skovronsky is Chief Scientific and Product Officer; Jacob Van Naarden heads corporate business development.
  • Company profile: founded 10 May 1876; the About page lists an access to medicines program, the Lilly Foundation and a Lilly Grant Office for health-professional education grants.

Timeline

  1. 1876Company founded.
  2. 2026Asset sale agreement with Sangamo signed; Sangamo files Chapter 11.
  3. 2026Sangamo tells the CJD Foundation family conference that Lilly is the identified buyer and the program is expected to continue.
  4. 2026Lilly selected as successful bidder at USD 50 million cash.
  5. 2026Expected closing date given in August (on or about); actual date not stated.
  6. 2026Sangamo reports the Lilly sale has closed.
Sources for this page